CD274 and metabolic dysfunction-associated steatohepatitis: The published Nature article stated that “therapeutic PD1- or PD-L1-related immunotherapy failed to cause tumor regression in NASH–HCC” [76]; this statement did not apply to HCC with nonviral etiology as a whole, but to NASH-HCC only.